Wednesday, 26 August 2026European Markets

ADC SIIC Stock Bullish Momentum With A 11.11% Rise Today

Loading stream...

(vianews) - the market ended the session with adc siic (aldv.pa) jumping 11.11% to €0.06 on wednesday, after five successive sessions in a row of losses. cac 40 slid 1.35% to €7,315.07, after two sequential sessions in a row of losses, on what was an all-around down trend exchanging session today.

adc siic's last close was €0.05, 32.5% under its 52-week high of €0.08.

about adc siic

alliance developpement capital siic (adc siic) is a publicly owned real estate investment firm. the firm specializes in owning and managing residential real estate properties. it primarily invests in properties in paris and its suburbs. the firm was formerly known as ad capital sa. alliance developpement capital is based in saint-josse-ten-noode, belgium.

earnings per share

as for profitability, adc siic has a trailing twelve months eps of €-0.01.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -1.87%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, adc siic's stock is considered to be overbought (>=80).

more news about adc siic (aldv.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com